BostonGene
AI models of tumor and immune biology applied to precision oncology, serving both clinical care and drug development. The Tumor Portrait test integrates DNA and RNA exome sequencing into a single end to end assay, approved under CLIA, CAP, and the New York State Department of Health, producing tumor driver, microenvironment, and actionable biomarker characterization from one sample. Kassandra is the company's cell deconvolution model for reconstructing tumor microenvironment composition. Clinical and analytical validation was published in Communications Medicine, part of the Nature portfolio, across more than 2,200 tumors, reporting high reproducibility and clinical actionability in 98 percent of cases. Research collaborations span MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, with nine abstracts accepted at ASCO 2026, and biopharma partnerships include Takeda for trial design and biomarker signature identification. A Japan joint venture operates with NEC Corporation and Japan Industrial Partners.
Capability Axes
Higher than most in this lane because the models carry more of the product: the company positions an AI foundation model of tumor and immune biology, with Kassandra performing cell deconvolution to reconstruct the tumor microenvironment from sequencing data, an inference task rather than a measurement. Held back from A because Tumor Portrait remains a DNA and RNA exome assay run in the company's own regulated laboratory, so the wet lab is still load bearing, consistent with how GRAIL, Freenome, Caris, and GeneDx are graded.
Clinical and analytical validation of the combined RNA and DNA exome assay was published in Communications Medicine, part of the Nature portfolio, across more than 2,200 tumors, reporting high reproducibility and clinical actionability in 98 percent of cases. Publishing a validation study of the assay that underpins the AI, in a peer reviewed venue with a stated cohort size, is the standard this axis asks for. Corroborated by nine abstracts accepted at ASCO 2026 developed with MD Anderson, Weill Cornell, and the Parker Institute.
Regulatory position is stated plainly: the Tumor Portrait platform is approved under CLIA, CAP, and the New York State Department of Health, the standard framework for a laboratory developed test, and New York State approval is a meaningfully higher bar than CLIA alone. No FDA clearance or approval is claimed, and none is implied. Held back from A because no FDA pathway or timeline is disclosed for products where one might eventually apply.
No public pricing. Contact the vendor. Two commercial surfaces with different structures: clinical testing ordered by providers, and separately negotiated biopharma research and development partnerships such as the announced Takeda collaboration. No rate card published for either.
Clearly bounded: oncology and immune mediated disease, spanning clinical care through the provider facing Tumor Portrait test and drug development through biopharma partnerships. The company states both surfaces explicitly rather than implying general applicability.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact the vendor
|
Per test through diagnostic channels; separate biopharma partnership agreements | — | — | Vendor Published |
Two commercial surfaces with different structures and no published rate card for either: clinical Tumor Portrait testing ordered by providers and billed through diagnostic channels, and separately negotiated biopharma partnerships for trial design, patient selection, and biomarker work, such as the announced Takeda collaboration.